Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) to Post Q2 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSFree Report) – Leerink Partnrs cut their Q2 2024 earnings estimates for shares of Marinus Pharmaceuticals in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of ($0.59) per share for the quarter, down from their previous forecast of ($0.48). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.00) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q3 2024 earnings at ($0.37) EPS, Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($1.75) EPS, FY2025 earnings at ($0.70) EPS, FY2026 earnings at ($0.10) EPS and FY2028 earnings at $0.70 EPS.

A number of other analysts have also issued reports on the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. StockNews.com cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Truist Financial reduced their target price on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Oppenheimer reaffirmed a “market perform” rating and set a $9.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.79.

View Our Latest Report on Marinus Pharmaceuticals

Marinus Pharmaceuticals Stock Up 1.5 %

Shares of NASDAQ:MRNS opened at $1.35 on Monday. The business has a 50-day moving average price of $5.85 and a 200 day moving average price of $7.77. Marinus Pharmaceuticals has a 12-month low of $1.11 and a 12-month high of $11.26. The company has a current ratio of 3.07, a quick ratio of 2.93 and a debt-to-equity ratio of 5.68. The company has a market capitalization of $74.16 million, a price-to-earnings ratio of -0.51 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Free Report) last issued its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. The firm had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $7.78 million. During the same period last year, the firm earned ($0.76) earnings per share.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Eventide Asset Management LLC raised its stake in Marinus Pharmaceuticals by 42.8% during the 3rd quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock valued at $36,466,000 after acquiring an additional 1,356,800 shares during the last quarter. Jennison Associates LLC increased its stake in Marinus Pharmaceuticals by 58.4% in the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after buying an additional 1,089,913 shares during the period. abrdn plc acquired a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth $6,006,000. Superstring Capital Management LP purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $5,027,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Marinus Pharmaceuticals by 6.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after acquiring an additional 173,226 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Further Reading

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.